Amalgamated Bank’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-34,726
| Closed | -$1.4M | – | 1636 |
|
|
2026
Q1 | $1.4M | Buy |
34,726
+25,990
| +298% | +$560K | 0.01% | 949 |
|
|
2025
Q4 | $219K | Buy |
8,736
+62
| +0.7% | +$1.46K | ﹤0.01% | 1548 |
|
|
2025
Q3 | $196K | Buy |
8,674
+563
| +7% | +$13.1K | ﹤0.01% | 1575 |
|
|
2025
Q2 | $140K | Buy |
8,111
+866
| +12% | +$16K | ﹤0.01% | 1639 |
|
|
2025
Q1 | $158K | Buy |
7,245
+291
| +4% | +$8.04K | ﹤0.01% | 1587 |
|
|
2024
Q4 | $222K | Sell |
6,954
-41
| -0.6% | -$1.23K | ﹤0.01% | 1549 |
|
|
2024
Q3 | $202K | Hold |
6,995
| – | – | ﹤0.01% | 1580 |
|
|
2024
Q2 | $268K | Buy |
6,995
+359
| +5% | +$16.3K | ﹤0.01% | 1501 |
|
|
2024
Q1 | $390K | Sell |
6,636
-13,821
| -68% | -$881K | ﹤0.01% | 1404 |
|
|
2023
Q4 | $1.23M | Sell |
20,457
-1,728
| -8% | -$87.7K | 0.01% | 1083 |
|
|
2023
Q3 | $844K | Buy |
22,185
+763
| +4% | +$33.5K | 0.01% | 1183 |
|
|
2023
Q2 | $1.95M | Buy |
21,422
+8,128
| +61% | +$701K | 0.02% | 897 |
|
|
2023
Q1 | $877K | Sell |
13,294
-2,109
| -14% | -$122K | 0.01% | 1161 |
|
|
2022
Q4 | $796K | Buy |
15,403
+231
| +2% | +$12.3K | 0.01% | 1243 |
|
|
2022
Q3 | $1.04M | Buy |
15,172
+772
| +5% | +$45.7K | 0.01% | 1093 |
|
|
2022
Q2 | $651K | Buy |
14,400
+1,936
| +16% | +$88.3K | 0.01% | 1337 |
|
|
2022
Q1 | $633K | Sell |
12,464
-87
| -0.7% | -$3.84K | ﹤0.01% | 1449 |
|
|
2021
Q4 | $593K | Buy |
12,551
+997
| +9% | +$39.3K | ﹤0.01% | 1498 |
|
|
2021
Q3 | $381K | Sell |
11,554
-711
| -6% | -$39.9K | ﹤0.01% | 1723 |
|
|
2021
Q2 | $775K | Buy |
12,265
+3,715
| +43% | +$192K | 0.01% | 1409 |
|
|
2021
Q1 | $367K | Sell |
8,550
-833
| -9% | -$39.4K | 0.01% | 1146 |
|
|
2020
Q4 | $537K | Buy |
9,383
+51
| +0.5% | +$2.16K | 0.02% | 925 |
|
|
2020
Q3 | $282K | Sell |
9,332
-282
| -3% | -$8.43K | 0.01% | 1139 |
|
|
2020
Q2 | $314K | Buy |
9,614
+127
| +1% | +$4.08K | 0.01% | 1083 |
|
|
2020
Q1 | $254K | Buy |
9,487
+748
| +9% | +$26.6K | 0.01% | 1228 |
|
|
2019
Q4 | $268K | Buy |
8,739
+162
| +2% | +$4.48K | ﹤0.01% | 1475 |
|
|
2019
Q3 | $207K | Sell |
8,577
-80
| -0.9% | -$2.2K | ﹤0.01% | 1527 |
|
|
2019
Q2 | $219K | Buy |
+8,657
| New | +$176K | 0.01% | 1533 |
|
Other funds holding APLS
Amalgamated Bank's APLS Position: Q2 2026 in Review
Amalgamated Bank sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 34,726 shares — an estimated $1.4M sold.
Amalgamated Bank first reported a position in APLS in Q2 2019 and held it in 28 quarters. The position peaked at $1.95M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Amalgamated Bank reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Amalgamated Bank sold 34,726 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.4M.
- Amalgamated Bank first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 28 quarters.
- Amalgamated Bank's Apellis Pharmaceuticals position peaked at $1.95M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.